Statistically equivalent to Dap in a trial purposely designed NOT to have enough statistical power necessary to draw accurate conclusions about efficacy in a population using sample data.
Non significant studies always raise more questions about the reliability and validity of data, methodology adopted, sampling and data analysis and how that information is often twisted and presented to shareholders by snake oil salesmen.
Good point for everyone to know. And how many doses did it take for Daptomycin to be statistically equal to one dose Brilacidin? If you want to speak about the Brilacidin ABSSSI trial you should not be afraid to tell the full story.